vTv Therapeutics Overview
- Status
-
Public
- Employees
-
26
- Stock Symbol
-
VTVT
- Investments
-
1
- Share Price
-
$19.32
- (As of Friday Closing)
vTv Therapeutics General Information
Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Contact Information
Website
www.vtvtherapeutics.comCorporate Office
- 3980 Premier Drive
- Suite 110
- High Point, NC 27265
- United States
Corporate Office
- 3980 Premier Drive
- Suite 110
- High Point, NC 27265
- United States
vTv Therapeutics Timeline
vTv Therapeutics Stock Performance
As of 13-Nov-2026, vTv Therapeutics’s stock price is $19.32. Its current market cap is $79M with 4.01M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $19.32 | $20.69 | $19.04 - $44.00 | $79M | 4.01M | 35.6K | -$0.62 |
vTv Therapeutics Financials Summary
As of 30-Sep-2026, vTv Therapeutics has a trailing 12-month revenue of $36.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 35,296 | 59,337 | (2,381) | 26,762 |
| Revenue | 36,839 | 0 | 1,017 | 0 |
| EBITDA | (10,921) | (32,928) | (24,081) | (26,335) |
| Net Income | (7,678) | (26,974) | (18,462) | (20,250) |
| Total Assets | 78,607 | 89,899 | 38,266 | 11,018 |
| Total Debt | 67 | 0 | 169 | 529 |
vTv Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
vTv Therapeutics Comparisons
Industry
Financing
Details
vTv Therapeutics Competitors (50)
One of vTv Therapeutics’s 50 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| PharmaCyte Biotech | Corporation | Las Vegas, NV | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA |
vTv Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
vTv Therapeutics Patents
vTv Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3233453-A1 | Solid composition of glp-1 receptor agonist | Pending | 28-Sep-2021 | ||
| EP-4410793-A1 | Solid composition of glp-1 receptor agonist | Pending | 28-Sep-2021 | ||
| EP-4410793-A4 | Solid composition of glp-1 receptor agonist | Pending | 28-Sep-2021 | ||
| US-20250332157-A1 | Solid composition of glp-1 receptor agonist | Pending | 28-Sep-2021 | ||
| WO-2023051490-A1 | Solid composition of glp-1 receptor agonist | Inactive | 28-Sep-2021 | A61K31/4741 |
vTv Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
vTv Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
vTv Therapeutics Investments (1)
vTv Therapeutics’s most recent deal was a Early Stage VC with Anteris Bio for . The deal was made on 11-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Anteris Bio | 11-Dec-2020 | Early Stage VC | Drug Discovery |
vTv Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.48 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
vTv Therapeutics Exits (1)
vTv Therapeutics’s most recent exit was on 11-Dec-2020 from Anteris Bio. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Anteris Bio | 11-Dec-2020 | Completed |
|
vTv Therapeutics FAQs
-
Where is vTv Therapeutics headquartered?
vTv Therapeutics is headquartered in High Point, NC.
-
What is the size of vTv Therapeutics?
vTv Therapeutics has 26 total employees.
-
What industry is vTv Therapeutics in?
vTv Therapeutics’s primary industry is Biotechnology.
-
Is vTv Therapeutics a private or public company?
vTv Therapeutics is a Public company.
-
What is vTv Therapeutics’s stock symbol?
The ticker symbol for vTv Therapeutics is VTVT.
-
What is the current stock price of vTv Therapeutics?
As of 13-Nov-2026 the stock price of vTv Therapeutics is $19.32.
-
What is the current market cap of vTv Therapeutics?
The current market capitalization of vTv Therapeutics is $79M.
-
What is vTv Therapeutics’s current revenue?
The trailing twelve month revenue for vTv Therapeutics is $36.8M.
-
Who are vTv Therapeutics’s competitors?
NGM Biopharmaceuticals, PharmaCyte Biotech, Genetix Biotherapeutics, TScan Therapeutics, and Fate Therapeutics are some of the 50 competitors of vTv Therapeutics.
-
What is vTv Therapeutics’s annual earnings per share (EPS)?
vTv Therapeutics’s EPS for 12 months was -$0.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
